Mutational Analysis of the Nucleotide Binding Sites of the Yeast Vacuolar Proton-translocating ATPase*

Kathryn J. MacLeod, Elena Vasilyeva, James D. BalejaDagger , and Michael Forgac§

From the Departments of Cellular and Molecular Physiology and Dagger  Biochemistry, Tufts University School of Medicine, Boston, Massachusetts 02111

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

To further define the structure of the nucleotide binding sites on the vacuolar proton-translocating ATPase (V-ATPase), the role of aromatic residues at the catalytic sites was probed using site-directed mutagenesis of the VMA1 gene that encodes the A subunit in yeast. Substitutions were made at three positions (Phe452, Tyr532, and Phe538) that correspond to residues observed in the crystal structure of the homologous beta  subunit of the bovine mitochondrial F-ATPase to be in proximity to the adenine ring of bound ATP. Although conservative substitutions at these positions had relatively little effect on V-ATPase activity, replacement with nonaromatic residues (such as alanine or serine) caused either a complete loss of activity (F452A) or a decrease in the affinity for ATP (Y532S and F538A). The F452A mutation also appeared to reduce stability of the V-ATPase complex. These results suggest that aromatic or hydrophobic residues at these positions are essential to maintain activity and/or high affinity binding to the catalytic sites of the V-ATPase.

Site-directed mutations were also made at residues (Phe479 and Arg483) that are postulated to be contributed by the A subunit to the noncatalytic nucleotide binding sites. Generally, substitutions at these positions led to decreases in activity ranging from 30 to 70% relative to wild type as well as modest decreases in Km for ATP. Interestingly, the R483E and R483Q mutants showed a time-dependent increase in ATPase activity following addition of ATP, suggesting that events at the noncatalytic sites may modulate the catalytic activity of the enzyme.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The vacuolar proton-translocating ATPases (or V-ATPases)1 are a class of enzymes that couple the hydrolysis of ATP to the transmembrane movement of protons. This proton movement results in the generation of a pH gradient and the acidification of intracellular compartments (1-9) or, for certain specialized cells, the extracellular space (10-12). The V-ATPases therefore play an essential role in many basic cellular functions which require acidification, including protein processing and degradation, receptor-mediated endocytosis, intracellular membrane trafficking, and coupled transport (for review, see Refs. 1-9).

The V-ATPases are composed of two domains, a 500-kDa peripheral V1 domain with the structure A3B3C1D1E1F1G1H1, which is responsible for ATP hydrolysis, and a 250-kDa V0 domain with the structure a1d1c"1(c,c')6, that is responsible for proton translocation (1, 13). In Saccharomyces cerevisiae, the V-ATPase subunits are encoded by at least 14 genes, including VMA1, which encodes the 69-kDa A subunit (14, 15), and VMA2, encoding the 60-kDa B subunit (16). Sequence homology indicates that the A and B subunits of the V-ATPases (14-22) are related to the beta  and alpha  subunits, respectively, of the F-type ATPases (F-ATPases), which function in mitochondria, chloroplasts, and bacteria to synthesize ATP (23-28). The level of sequence identity between these proteins is only 20-25%, however, and the A subunit contains a large (100-amino acid) insertion not present in beta , suggesting that significant structural and functional differences may exist between these proteins.

From the x-ray crystal structure of the F1 domain from bovine heart mitochondria it was confirmed that the nucleotide binding sites are at the interface between the beta  and alpha  subunits, with the catalytic site primarily on beta  and the noncatalytic site primarily on alpha  (29). Previous biochemical experiments on the V-ATPase suggest that the catalytic nucleotide binding site is located on the A subunit while the noncatalytic site resides on the B subunit. For the catalytic site, these data include ATP-protectable labeling of the A subunit by reagents such as N-ethylmaleimide and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole, which correlates with inhibition of activity (for references, see Forgac (30)). In addition, modification of a single A subunit cysteine residue (Cys254 of the bovine A subunit) by N-ethylmaleimide, cystine, or by disulfide bond formation with Cys532, leads to inactivation of the enzyme (31-33). Also, labeling of the A subunit by the photoaffinity ATP analog 2-[azido-32P]ATP correlates well with inhibition by this reagent (34). Finally, the A subunit, unlike the B subunit, contains several consensus sequences that appear to be critical for ATP hydrolysis in the homologous beta  subunit (35-37), including the glycine-rich loop.

There is limited information concerning the structure of the nucleotide binding sites on the V-ATPase, although mutagenesis studies in yeast have begun to identify residues important for V-ATPase activity (38-40). To investigate residues involved in formation of the nucleotide binding sites, site-directed mutagenesis of the VMA1 gene in yeast was performed. Based on the crystal structure of the F1 beta  subunit and sequence alignment of the beta and A subunits, mutations were made in several residues proposed to form part of the adenine binding pocket at the catalytic site, including Phe452, Tyr532, and Phe538 (corresponding to Tyr345, Phe418, and Phe424, respectively, of the bovine mitochondrial beta  subunit) (29). In addition, mutations were constructed at two residues, Phe479 and Arg483 (corresponding to Tyr368 and Arg372 of the bovine F1 beta ) (29), which are postulated to be contributed by the A subunit to the noncatalytic nucleotide binding sites. The effects of these mutations on activity, kinetics and assembly of the V-ATPase complex were assessed.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials and Strains-- Zymolyase 100T was obtained from Sekagaku America, Inc. Concanamycin A was obtained from Fluka Chemical Corp. Tran35S-label was purchased from ICN Biomedicals. Leupeptin, aprotinin, and pepstatin were all purchased from Boehringer Mannheim. Yeast extract, dextrose, peptone, and yeast nitrogen base were purchased from Difco. Zwittergent 3-14 was purchased from Calbiochem-Novabiochem Corp. Molecular biology reagents were from Promega and New England Biolabs. ATP and most other chemicals were purchased from Sigma.

Yeast strain SF838-5Aalpha vma1Delta -8 (MATalpha , leu2-3, 112, ura3-52, ade6, vma1Delta ::LEU2), used for integrations and subsequent biochemical characterization, was a kind gift from Dr. Patricia Kane, Department of Biochemistry and Molecular Biology, SUNY, Syracuse. The plasmid pPK17-7, containing VMA1 lacking the entire VMA1-derived endonuclease subcloned into the yeast shuttle vector pSEYC68 at BamHI and SalI sites (15, 39) was from Dr. Kane. Yeast cells were grown in yeast extract-peptone-dextrose (YEPD) medium or in supplemented synthetic dextrose medium.

Mutagenesis-- Mutagenesis was performed on the wild type VMA1 cDNA using the Altered Sites II in vitro mutagenesis system (Promega) following the manufacturer's protocol. The full-length VMA1 cDNA lacking the endonuclease spacer region (15) was cloned into pAlter-1 using BamHI and SalI sites. The mutagenesis oligonucleotides were as follows with the substitution sites underlined: F452Y, GAAAGCATTACCCATCTATC; F452W, CAAAGAAAGCATTGGCCATCTATCAAC; F452A, CAAAGAAAGCATGCCCCATCTATCAAC; F479Y, CAATTACCCTGAATATCCTGTTTTAAG; F479A, CAATTACCCTGAAGCTCCTGTTTTAAGAG; F479W, CAATTACCCTGAATGGCCTGTTTTAAGAG; R483K, GAATTTCCTGTTTTAAAAGATCGTATG; R483E, GAATTTCCTGTTTTAGAAGATCGTATGAAG; R483Q, GAATTTCCTGTTTTACAAGATCGTATGAAG; Y532F, CAACAAAATGGTTTCTCCACTTATG; Y532S, CAACAAAATGGTTCCTCCACTTATGATG; F538Y, CACTTATGATGCTTACTGTCCAATTTGG; F538W, CACTTATGATGCTTGGTGTCCAATTTGG; and F538A, CACTTATGATGCTGCCTGTCCAATTTGG.

All mutations were confirmed by DNA sequencing using the dideoxy method. Cassettes containing each mutation were subcloned using HpaI and SalI into a wild type pAlterI/VMA1 plasmid that had not been subjected to mutagenesis. The full-length mutant vma1 cDNAs were then subcloned, along with wild type VMA1 for a positive control, into the yeast integration vector YIp5 (New England Biolabs) using BamHI and SalI sites.

Transformation-- Wild type VMA1 in YIp5 (WT-VMA1) as a positive control, YIp5 vector alone (vma1Delta /YIp5) as a negative control, or vma1 mutant YIp5 plasmids were linearized with ApaI to target the integration of the constructs to the URA3 locus. Yeast cells SF838-5Aalpha vma1Delta -8 were transformed with the linearized constructs using the lithium acetate method (41). The transformants were then selected on Ura- plates as described previously (42). Chromosomal DNA was isolated from the transformed yeast cells and the VMA1 gene was amplified by a polymerase chain reaction. The presence of the site-directed mutations was confirmed by sequencing the polymerase chain reaction products. Growth phenotypes of the mutants were assessed on YEPD plates buffered with 50 mM KH2PO4 and 50 mM succinic acid to either pH 5.5 or 7.5. Plates containing 50 mM CaCl2 were buffered to pH 7.5 using 50 mM MES/MOPS (43).

Purification of the V-ATPase Enzyme-- Yeast integrated with either wild type plasmid (WT-VMA1), vma1 mutant plasmids, or the vector YIp5 alone (vma1Delta /YIp5) as a negative control were cultured overnight in 1 liter of YEPD pH 5.5 to log phase. Vacuoles were isolated as described previously (44). For purification of the V-ATPase, vacuolar membranes were washed three times with 10 mM Tris-HCl, pH 7.5, and 1 mM EDTA, and solubilized in buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, and 2 mM dithiothreitol) with Zwittergent 3-14, and the V-ATPase was isolated by glycerol density gradient sedimentation on 20-50% glycerol gradients as described previously (45).

Immunoblot Analysis-- Whole cell lysates and solubilized vacuoles were prepared using 50 mM Tris-HCl, pH 6.8, 8 M urea, 5% SDS, 1 mM EDTA, and 5% beta -mercaptoethanol, as described previously (46). Samples were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with the monoclonal antibody 8B1-F3 against the yeast V-ATPase A subunit (Molecular Probes, Inc.), followed by horseradish peroxidase-conjugated secondary antibody (Bio-Rad). Immunoblots were developed using a chemiluminescent detection method following the manufacturer's protocol from Kirkegaard & Perry Laboratories.

Metabolic Labeling and Immunoprecipitation of the V-ATPase-- Yeast strains WT-VMA1, vma1Delta /YIp5, and vma1 mutants were grown in synthetic dextrose-methionine-free medium overnight, converted to spheroplasts, and metabolically labeled with Tran35S-label (50 µCi/5 × 106 spheroplasts) for 60 min at 30 °C. Spheroplasts were pelleted, washed, and lysed in solubilization buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 10% glycerol) with C12E9, and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 5 µg/ml aprotinin, 1 µg/ml pepstatin). The V-ATPase was cross-linked using dithiobis(succinimidyl propionate) and immunoprecipitated using the monoclonal antibody 8B1-F3 against the yeast A subunit and protein A-Sepharose (Pharmacia Biotech Inc.). Samples were subjected to SDS-PAGE on a 12% acrylamide gel, fixed in 30% methanol and 7.5% acetic acid for 1 h, incubated in Enlightning solution (NEN Life Science Products) for 30 min, dried, and analyzed using autoradiography.

Modeling of the Catalytic Nucleotide Binding Site on the V-ATPase A Subunit-- A model for the V-ATPase was created from the 2.8 Å resolution structure of bovine heart mitochondrial F1-ATPase (29). The amino acid sequences were first aligned using the Genetics Computer Group (GCG) sequence analysis software package. Approximately 23% sequence identity was obtained after sequence alignment, with good agreement in predicted secondary structure (47). The positions of insertions and deletions created by the alignment procedure were examined on the model of F1-ATPase using InsightII (Biosym Technologies, San Diego, CA), and were found to be mostly in loops at the surface of the molecule. A few were located within secondary structure elements and the sequence alignment was adjusted to move these by a few residues to the end of the structural elements. The large insertion of about 100 amino acids present in the A subunit (but not beta ) was not modeled. The resultant structure now containing the amino acid sequence of V-ATPase was subjected to 200 steps of energy minimization using X-PLOR (48).

Other Procedures-- ATPase activity was measured using a coupled spectrophotometric assay (44) in the absence or presence of 1 µM concanamycin A, a specific V-ATPase inhibitor (49). ATPase assays performed on vacuoles or on purified enzyme contained 1 mM ATP, 2 mM MgCl2 and were done at 37 °C. SDS-PAGE was carried out as described by Laemmli (50). Protein concentrations were determined by Lowry et al. (51) assay, and determinations on purified enzyme included initial protein precipitation with 10% trichloroacetic acid.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Growth Phenotypes for vma1 Mutants-- Site-directed mutations of the VMA1 cDNA encoding the yeast V-ATPase A subunit were constructed as described under "Experimental Procedures." Three of the residues mutated, Phe452, Tyr532, and Phe538, are located in the C-terminal domain of the A subunit and are candidates for contributing to the adenine binding pocket of the catalytic nucleotide binding site. Two additional A subunit residues, Phe479 and Arg483, are postulated on the basis of sequence alignment and the crystal structure of F1 to form part of the noncatalytic nucleotide binding site located on the B subunit. The mutant vma1 cDNAs were subcloned into the yeast integration vector YIp5 and expressed in a vma1Delta strain in which the VMA1 gene was deleted. The deletion of genes encoding subunits of the V-ATPase results in a conditional lethal phenotype (14, 15, 52), which is also used to screen for mutants defective in vacuolar acidification. These strains are able to grow on medium buffered to acidic pH (5.0-5.5) but are unable to grow at neutral pH (7.5) or in neutral medium containing 50 mM CaCl2. Table I summarizes the growth phenotypes for these vma1 mutants. The wild type strain WT-VMA1 grew under each condition and the negative control vma1Delta /YIp5 strain exhibited the expected conditional lethal phenotype. F452A was unable to grow at pH 7.5 in the absence or presence of elevated extracellular calcium, exhibiting a growth phenotype similar to the vma1Delta strain. F538W was unable to grow at pH 7.5 in the presence of high calcium. The remaining mutants, including those at the noncatalytic site, showed relatively normal growth at pH 7.5. It has previously been determined that 20% of V-ATPase activity is sufficient to rescue the growth phenotype (39). These results thus suggest that the F452A and F538W mutants are deficient in vacuolar acidification, but that the remainder of the mutant strains have a V-ATPase activity that is at least 20% of wild-type. It was next necessary to determine whether these mutations directly caused a loss of V-ATPase activity.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Characterization of growth phenotypes of wild type and vma1 mutants
Wild-type VMA1 in the yeast integration vector YIp5 (WT-VMA1), the deletion strain vma1Delta with the vector YIp5 alone (vma1Delta /YIp5) as a negative control, and the vma1 mutant strains were plated on YEPD plates buffered to pH 5.5, 7.5, or 7.5 containing 50 mM CaCl2. Growth was assessed after 5 days at 30°C. ++, good growth; +, partial growth; -, no growth.

ATPase Activities in Purified Vacuoles from vma1 Mutants-- Fig. 1 shows the V-ATPase activities of the wild type WT-VMA1, vma1Delta /YIp5, and vma1 mutant strains. Fig. 1A shows the relative ATPase activities for the strains containing mutations at the catalytic site, and Fig. 1B the activities for the strains with the proposed noncatalytic site mutations. V-ATPase activities were measured in isolated vacuoles using a coupled spectrophotometric assay at 1 mM ATP and 37 °C as described under "Experimental Procedures." Activities are expressed relative to the WT-VMA1 strain, defined as 100%, which had a specific activity of 0.19 (± 0.04) µmol of ATP/min/mg protein.2 The negative control, vma1Delta /YIp5 strain, had no measurable activity. F452Y, Y532F, F538Y, and F538A had nearly wild type levels of activity, whereas F452W and Y532S had approximately 50% and F538W had 20% of wild type levels. F452A had less than 5% of wild type activity and was comparable to the deletion strain. Mutations at the noncatalytic site all appear to reduce activity by 30-70% as shown in Fig. 1B. These data are consistent with the growth phenotypes.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of vma1 mutations on concanamycin A-sensitive ATPase activity in isolated yeast vacuoles. ATPase activity was measured on aliquots of purified vacuoles (10 µg of protein) as described under "Experimental Procedures." Activities are expressed relative to that of vacuoles isolated from the WT-VMA1 strain (defined as 100%), which had a specific activity of 0.19 µmol of ATP/min/mg of protein at 1 mM ATP (see footnote 2). No measurable ATPase activity was observed in vacuoles isolated from the negative control, vma1Delta /YIp5, containing the vector alone. Each bar represents the average of two or three determinations made on two or three independent vacuolar membrane preparations. A shows the relative ATPase activities for the strains containing mutations at the catalytic site, and B the activities for the strains with mutations at the noncatalytic site.

A Subunit Expression and V-ATPase Assembly in vma1 Mutants-- It was next necessary to determine whether the observed decrease in activity was due to decreased protein levels or to decreased V-ATPase assembly. Fig. 2 shows the effects of the mutations on A subunit stability and the presence of the A subunit on the vacuolar membrane, which provides an initial measure of V-ATPase assembly. Fig. 2 is an immunoblot using the monoclonal antibody 8B1-F3 against the yeast A subunit to determine levels of the A subunit in either whole cell lysates (CELL) or isolated vacuoles (VAC). The top panel shows the immunoblots for the wild type WT-VMA1 and for vma1Delta /YIp5. The middle and bottom panels show the immunoblots for the strains containing mutations at the catalytic site, and the proposed noncatalytic site, respectively. Of the mutations tested, only R483E showed somewhat lower levels of A subunit in the whole cell lysate compared with the wild type. However, all of the mutated proteins, including R483E, showed normal levels of A subunit on the vacuolar membrane.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of vma1 mutations on A subunit stability and A subunit levels in vacuolar membranes. Whole cell lysates (CELL) and purified vacuoles (VAC) (5 µg of protein) were prepared from WT-VMA1, vma1Delta /YIp5, and vma1 mutant strains, subjected to SDS-PAGE on a 12% acrylamide gel, transferred to nitrocellulose, and immunoblotted using the monoclonal antibody 8B1-F3 against the yeast A subunit, as described under "Experimental Procedures." The top panel shows the immunoblots for the wild type WT-VMA1 and for vma1Delta /YIp5. The middle panel and bottom panel show the immunoblots for the strains containing mutations at the catalytic site, and the proposed noncatalytic site, respectively.

As a further test of assembly, the V-ATPase was immunoprecipitated from metabolically labeled cells. Cells were converted to spheroplasts and labeled with Tran35S-label for 60 min at 30 °C followed by cell lysis, detergent solubilization, and immunoprecipitation using the monoclonal antibody 8B1-F3 as described under "Experimental Procedures." As can be seen in Fig. 3A, most of the mutants at the catalytic site showed normal assembly relative to wild type. An exception is the mutant F452A, which shows very little intact V-ATPase complex by immunoprecipitation. Because this mutant showed normal levels of A subunit on the vacuolar membrane (Fig. 2) and normal assembly following detergent solubilization and density gradient sedimentation (data not shown), it appears that this mutation has resulted in a destabilization of the complex such that it can no longer survive immunoprecipitation. Fig. 3B shows immunoprecipitation of the V-ATPase from the noncatalytic site mutants. As can be seen, none of the mutations dramatically reduces assembly, although F479W and R483E show somewhat lower labeling in the B subunit region. The possible significance of these results is discussed below.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of vma1 mutations on V-ATPase assembly as assessed by immunoprecipitation from 35S-labeled cells. Yeast strains WT-VMA1, vma1Delta /YIp5, and vma1 mutant strains were grown in methionine-free medium overnight, converted to spheroplasts, and metabolically labeled with Tran35S-label (50 µCi/5 × 106 spheroplasts) for 60 min at 30 °C. The V-ATPase was solubilized using C12E9 and immunoprecipitated using the monoclonal antibody 8B1-F3 against the yeast A subunit and protein A-Sepharose, and samples were subjected to SDS-PAGE on a 12% acrylamide gel and autoradiography performed as described under "Experimental Procedures." A shows the immunoprecipitations for the strains containing mutations at the catalytic site, and B the immunoprecipitations for the strains with mutations at the noncatalytic site.

Kinetic Analysis of vma1 Mutants-- To determine if any of the mutations resulted in changes in KmATP or Vmax for ATP hydrolysis, kinetic analysis on the purified enzymes was performed (Table II). Vacuoles were isolated from wild type WT-VMA1 and vma1 mutant strains and the V-ATPases were solubilized and purified by glycerol density gradient sedimentation as described under "Experimental Procedures." ATPase activities of the purified enzymes were measured over a range of ATP concentrations from 100 µM to 2.5 mM ATP, while the MgCl2 was maintained at 1 mM above the ATP concentration. Km and Vmax values were calculated from double reciprocal plots of ATP concentration versus ATPase activity. WT-VMA1 had a specific activity of 1.8 (±0.1) µmol/min/mg of protein at 1 mM ATP, a Km of 0.72 (±0.19) mM ATP and a Vmax of 2.7 (±0.1) µmol/min/mg of protein. As shown in Table II, the Km and Vmax for F452Y and F538Y were not significantly different from wild type, whereas F452W, F538W, and Y532F had a decreased Km, suggesting an increase in substrate affinity. kcat/Km values for the former two mutations were reduced by about 2-fold, whereas for the Y532F mutation, a small increase in kcat/Km was observed. F538A had a Km value approximately 2 times that of WT-VMA1, suggesting a small decrease in ATP affinity. Because the reaction rate for the Y532S mutant showed no sign of saturating, even at the highest ATP concentrations tested (2.5 mM), precise values for Km and Vmax could not be determined (data not shown). However, we estimate that the Km for ATP is greater than 5 mM, thus reflecting a significant decrease in affinity relative to the wild type. Some of the mutations proposed to be at the noncatalytic site also resulted in kinetic changes. F479W, F479A, and R483K all showed significant decreases in both Km and Vmax, although values of kcat/Km were either unchanged (F479A) or reduced by at most 2-fold. Interestingly, both R483Q and R483E exhibited a time-dependent increase in ATPase activity, as depicted for the R483Q mutant in Fig. 4.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Kinetic analysis of WT-VMA1 and the vma1 mutants
ATPase activities were measured on purified enzymes from WT-VMA1 and vma1 mutant strains as described under "Experimental Procedures." ATPase activities on purified enzyme were measured over a range of ATP concentrations from 100 µM to 2.5 mM ATP, while the MgCl2 was maintained at 1 mM above the ATP concentration. Km and Vmax were calculated from double reciprocal plots of ATP concentration versus ATPase activity expressed in µmol/min/mg of protein.


View larger version (7K):
[in this window]
[in a new window]
 
Fig. 4.   Time-dependent increase in ATPase activity of R483Q. Time course of ATP hydrolysis measured using a coupled spectrophotometric assay on the purified enzyme isolated from the wild type WT-VMA1 (a) and from the mutant R483Q (b) as described under "Experimental Procedures." The y axis shows absorbance at 340 nm, which descreases as NADH is converted to NAD in the coupled assay. ATPase activities were measured at 2.5 mM ATP and 3.5 mM MgCl2.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Although mutagenesis has been employed in several studies to identify A subunit residues important for activity of the V-ATPases (39, 40, 53), there is currently no information concerning the residues that may participate in formation of the adenine binding pocket on the A subunit. In the F-ATPase beta  subunit, the adenine ring appears to be in close contact with a hydrophobic surface formed by aromatic rings, in particular Tyr345 of the bovine mitochondrial enzyme (29). To determine whether aromatic rings are important in this region of the A subunit, site-directed mutagenesis was performed on Phe452, Tyr532, and Phe538, located in the C-terminal domain of the A subunit. Conservative substitutions (such as Phe to Tyr and Tyr to Phe) as well as nonconservative substitutions (such as Phe to Ala or Tyr to Ser) were carried out. Substitution with a bulkier amino acid (Trp) was also performed.

From the data presented, it appears that an aromatic ring or a hydrophobic residue is important at each of these positions, particularly Phe452. Of the catalytic site mutations tested, none significantly reduced stability of the A subunit and only one (F452A) reduced stability of the V-ATPase complex as evidenced by the inability to immunoprecipitate the intact complex from metabolically labeled cells. With respect to their effects on activity of the V-ATPase complex, the conservative mutations F452Y, Y532F, and F538Y had little effect on enzyme activity whereas the F452W mutation reduced activity by 50-70%, although this mutation also resulted in a lower value for Km, suggesting an increased affinity for ATP. Interestingly, the F452A mutant, which could be isolated as an intact complex from vacuoles, was completely inactive, suggesting that an aromatic or sufficiently large hydrophobic residue at this position is crucial. Phe452 corresponds to Tyr345 of the mitochondrial beta  subunit, which appears from the crystal structure of F1 to be in direct contact with the adenine ring (29). Tyr345 of the mitochondrial beta  subunit is labeled by the photoaffinity analog 2-[azido-32P]ATP (54) and substitution of tryptophan for Tyr331 (which corresponds to Tyr345 in the Escherichia coli beta  subunit) results in a reduction in both Km and Vmax by about 2-fold (55), whereas substitution with alanine reduces Vmax by 5-fold and increases Km by 9-fold (56). It should be noted that substitution of leucine for Tyr331 in the E. coli F-ATPase results in a 7.5-fold increase in Km for ATP with little effect on Vmax (56), suggesting that a hydrophobic residue can partially substitute for the aromatic function at this position. Our data suggest that Phe452 plays a comparably important role in nucleotide binding to the catalytic site on the V-ATPase A subunit. The inability to immunoprecipitate the intact V-ATPase from cells bearing the F452A mutation suggests that this substitution may also lead to a reduced stability of the V-ATPase complex.

Mutations at Tyr532 and Phe538 had rather different effects on activity. In particular, Y532S appeared to show a significantly reduced affinity for ATP, again consistent with a role of this residue in ATP binding. This residue corresponds to Phe418 of the bovine mitochondrial beta  subunit which is situated near the end of the adenine binding pocket (29). Replacement of Phe538 with alanine also significantly reduced the affinity for ATP (approximately 2-fold), consistent with its interaction with the adenine ring. The corresponding residue in the F1 beta  subunit, Phe424, appears to interact with the adenine ring from the opposite side of Tyr345 (29). It should be noted that the effects of mutations in these beta  subunit residues (Phe418 and Phe424) on nucleotide binding to the F-ATPases have not been reported. These results support a model in which aromatic or hydrophobic residues in the C-terminal domain of the A subunit contribute to nucleotide binding to the catalytic site of the V-ATPase, with their absence resulting in substantial changes in either nucleotide binding or activity. These results also point up the likely similarity in structure of the catalytic nucleotide binding sites of the V and F-ATPases.

Using the recently released coordinates of the bovine heart mitochondrial F1 ATPase (29) and sequence alignment of the F-ATPase beta  subunit and V-ATPase A subunit, we have carried out energy minimization to arrive at a tentative model of the catalytic nucleotide binding site on the V-ATPase (Fig. 5). Shown are the aromatic residues investigated in the current study (Phe452, Tyr532, and Phe538) as well as A subunit residues previously characterized by site-directed mutagenesis (40), including Glu286, Lys263, Cys261, and Cys539. As for the beta  subunit, both Glu286 and Lys263 are in close proximity to the triphosphates of bound ATP, consistent with their proposed role in catalysis (29). Cys261 and Cys539 are predicted to be approximately 13 Å apart, suggesting that some distortion of the nucleotide binding site may need to occur in order for these two residues to undergo disulfide bond formation (33). All three aromatic residues are predicted to be in relatively close proximity to the adenine binding pocket, with Phe452 nearly stacked with the adenine ring. This is consistent with the mutagenesis data, where the largest effects on activity were observed with the F452A mutation.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   Proposed model for the catalytic nucleotide binding site of the yeast V-ATPase. Shown is an energy minimized model of the structure of the catalytic nucleotide binding site on the yeast V-ATPase A subunit based upon the x-ray crystal structure of the bovine mitochondrial F-ATPase beta  subunit (29) and sequence alignment of the A and beta  subunits (see "Experimental Procedures"). Shown are the aromatic residues mutated in the current study (Phe452, Tyr532 and Phe538). Also shown are two cysteine residues (Cys261 and Cys539) previously shown to form an inhibitory disulfide bond (33) as well as two residues (Lys263 and Glu286) shown by previous mutagenesis studies (39, 40) to be important for activity. The bound AMP-PNP molecule is shown in dark shading; the bound Mg2+ is shown in the lightly shaded sphere, and the water molecule involved in hydrolysis is shown in the darkly shaded sphere.

We have previously observed that mutations in B subunit residues postulated to be contributed to the catalytic site have dramatic effects on activity (38), suggesting that, as with the F-ATPases, the catalytic sites of the V-ATPases are located at the interface between the two nucleotide binding subunits. We also wished to determine the effects of mutations in A subunit residues postulated to be contributed to the noncatalytic sites on the B subunit. These include Phe479 (corresponding to Tyr368 of the bovine F1 beta  subunit) and Arg483 (corresponding to Arg372 of F1 beta ). This is particularly important as the function of the noncatalytic nucleotide binding sites remains uncertain. Interestingly, all the mutations tested (even the conservative F479Y and R483K mutations) decreased enzyme activity in purified vacuoles by 30-70% and reduced kcat/Km by at most 2-fold. These data are consistent with our previous findings that B subunit mutations at the noncatalytic site also resulted in modest (30-60%) decreases in activity (38). These results suggest that changes in the noncatalytic site produce an enzyme that is not substantially altered in its catalytic efficiency.

Although several of the mutations (including F479W and R483E) showed slightly reduced assembly as assessed by immunoprecipitation, none of them completely abolished assembly. On the other hand, both of these mutations showed somewhat reduced labeling of the 50-kDa region of the immunoprecipitates, which might reflect partial loss of the VMA13 gene product. Vma13p (a 54-kDa V1 subunit) is required for activity but not assembly of the V-ATPase complex (57). Among the most interesting mutations identified were R483E and R483Q, both of which resulted in a time-dependent increase in enzyme activity. One possible explanation for this effect is the loss during purification of the mutant enzymes of an endogenous nucleotide (possibly at the noncatalytic site) required for activity. This endogenous nucleotide would then be restored on addition to the assay. Alternatively, these mutations may result in slowed release of an inhibitory nucleotide which, in the wild type, is released rapidly. Sulfite has been suggested to activate the yeast V-ATPase by promoting the release of inhibitory ADP (58). Nevertheless, the effects of these mutations suggest that changes in the noncatalytic nucleotide binding sites can modulate the catalytic activity of the V-ATPase.

We have provided preliminary evidence for the role of A subunit residues Phe452, Tyr532, and Phe538 in formation of the catalytic nucleotide binding site of the V-ATPase, possibly through contribution to the adenine binding pocket. We have also demonstrated that mutations in residues on the A subunit, Phe479 and Arg483, that are postulated to form part of the noncatalytic site on the B subunit, can have effects on V-ATPase activity. Further work will be required to more completely define the function of these sites in the control of activity.

    ACKNOWLEDGEMENT

We thank Dr. Patricia Kane, Department of Biochemistry and Molecular Biology, SUNY, Syracuse, for the generous gift of the yeast strain SF838-5Aalpha vma1Delta -8, the plasmid pPK17-7, and for helpful discussions.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM 34478 (to M. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Cellular and Molecular Physiology, Tufts University, 136 Harrison Ave., Boston, MA 02111. Tel.: 617-636-6939; Fax: 617-636-0445.

1 The abbreviations used are: V-ATPase, vacuolar proton-translocating adenosine triphosphatase; YEPD, yeast extract-peptone-dextrose; PAGE, polyacrylamide gel electrophoresis; MES, 4-morpholineethanesulfonic acid; MOPS, 4-morpholinepropanesulfonic acid; AMP-PNP, 5'-adenylyl beta ,gamma -imidodiphosphate; PAGE, polyacrylamide gel electrophoresis; WT, wild type.

2 The specific activity reported is that for unwashed vacuoles at 1 mM ATP. Higher specific activities are obtained for washed vacuoles at saturating ATP concentrations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Stevens, T. H., and Forgac, M. (1997) Annu. Rev. Cell Dev. Biol. 13, 779-808 [CrossRef][Medline] [Order article via Infotrieve]
  2. Forgac, M. (1992) J. Bioenerg. Biomembr. 24, 341-350[Medline] [Order article via Infotrieve]
  3. Bowman, B. J., Vazquez-Laslop, N., and Bowman, E. J. (1992) J. Bioenerg. Biomembr. 24, 361-370[Medline] [Order article via Infotrieve]
  4. Kane, P. M., and Stevens, T. H. (1992) J. Bioenerg. Biomembr. 24, 383-394[Medline] [Order article via Infotrieve]
  5. Anraku, Y., Umemoto, N., Hirata, R., and Ohya, Y. (1992) J. Bioenerg. Biomembr. 24, 395-406[Medline] [Order article via Infotrieve]
  6. Sze, H., Ward, J. M., and Lai, S. (1992) J. Bioenerg. Biomembr. 24, 371-382[Medline] [Order article via Infotrieve]
  7. Gluck, S. L. (1992) J. Bioenerg. Biomembr. 24, 351-360[Medline] [Order article via Infotrieve]
  8. Kibak, H., Taiz, L., Starke, T., Bernasconi, P., and Gogarten, J. P. (1992) J. Bioenerg. Biomembr. 24, 415-424[Medline] [Order article via Infotrieve]
  9. Nelson, N. (1992) J. Bioenerg. Biomembr. 24, 407-414[Medline] [Order article via Infotrieve]
  10. Swallow, C. J., Grinstein, S., and Rotstein, O. D. (1990) J. Biol. Chem. 265, 7645-7654[Abstract/Free Full Text]
  11. Chatterjee, D., Chakraborty, M., Leit, M., Neff, L., Jamsa-Kellokumpu, S., Fuchs, R., and Baron, R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6257-6261[Abstract]
  12. Martinez-Zaguilan, R., Lynch, R., Martinez, G., and Gillies, R. (1993) Am. J. Physiol. 265, C1015-C1029[Abstract/Free Full Text]
  13. Arai, H., Terres, G., Pink, S., and Forgac, M. (1988) J. Biol. Chem. 263, 8796-8802[Abstract/Free Full Text]
  14. Hirata, R., Ohsumi, Y., Nakano, A., Kawasaki, H., Suzuki, K., and Anraku, Y. (1990) J. Biol. Chem. 265, 6726-6733[Abstract/Free Full Text]
  15. Kane, P. M., Yamashiro, C. T., Wolczyk, D. F., Neff, N., Goebl, M., Stevens, T. H. (1990) Science 250, 651-657[Medline] [Order article via Infotrieve]
  16. Nelson, H., Mandiyan, S., and Nelson, N. (1989) J. Biol. Chem. 264, 1775-1778[Abstract/Free Full Text]
  17. Zimniak, L., Dittrich, P., Gogarten, J. P., Kibak, H., Taiz, L. (1988) J. Biol. Chem. 263, 9102-9112[Abstract/Free Full Text]
  18. Bowman, E. J., Tenney, K., and Bowman, B. (1988) J. Biol. Chem. 263, 13994-14001[Abstract/Free Full Text]
  19. Bowman, B. J., Allen, R., Wechser, M. A., Bowman, E. J. (1988) J. Biol. Chem. 263, 14002-14007[Abstract/Free Full Text]
  20. Manolson, M. F., Ouellette, B. F., Filion, M., and Poole, R. (1988) J. Biol. Chem. 263, 17987-17994[Abstract/Free Full Text]
  21. Puopolo, K., Kumamoto, C., Adachi, I., and Forgac, M. (1991) J. Biol. Chem. 266, 24564-24572[Abstract/Free Full Text]
  22. Puopolo, K., Kumamoto, C., Adachi, I., Magner, R., and Forgac, M. (1992) J. Biol. Chem. 267, 3696-3706[Abstract/Free Full Text]
  23. Weber, J., and Senior, A. E. (1997) Biochim. Biophys. Acta 1319, 19-58[Medline] [Order article via Infotrieve]
  24. Fillingame, R. H. (1997) J. Exp. Biol. 200, 217-224[Abstract/Free Full Text]
  25. Cross, R. L., and Duncan, T. M. (1996) J. Bioenerg. Biomembr. 28, 403-408[Medline] [Order article via Infotrieve]
  26. Pedersen, P. L. (1996) Bioenerg. Biomembr. 28, 389-395 [Medline] [Order article via Infotrieve]
  27. Capaldi, R. A., Aggeler, R., Wilkens, S., and Gerhard, G. (1996) J. Bioenerg. Biomembr. 28, 397-401[Medline] [Order article via Infotrieve]
  28. Futai, M., and Omote, H. (1996) J. Bioenerg. Biomembr. 28, 409-414[Medline] [Order article via Infotrieve]
  29. Abrahams, J. P., Leslie, A. G., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628[CrossRef][Medline] [Order article via Infotrieve]
  30. Forgac, M. (1989) Physiol. Rev. 69, 765-796[Free Full Text]
  31. Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 5817-5822[Abstract/Free Full Text]
  32. Feng, Y., and Forgac, M. (1992) J. Biol. Chem. 267, 19769-19772[Abstract/Free Full Text]
  33. Feng, Y., and Forgac, M. (1994) J. Biol. Chem. 269, 13224-13230[Abstract/Free Full Text]
  34. Zhang, J., Vasilyeva, E., Feng, Y., and Forgac, M. (1995) J. Biol. Chem. 270, 15494-15500[Abstract/Free Full Text]
  35. Senior, A. E., and al-Shawi, M. K. (1992) J. Biol. Chem. 267, 21471-21478[Abstract/Free Full Text]
  36. Omote, H., Maeda, M., and Futai, M. (1992) J. Biol. Chem. 267, 20571-20576[Abstract/Free Full Text]
  37. Iwamoto, A., Park, M. Y., Maeda, M., and Futai, M. (1993) J. Biol. Chem. 268, 3156-3160.39[Abstract/Free Full Text]
  38. Liu, Q., Kane, P. M., Newman, P. R., Forgac, M. (1996) J. Biol. Chem. 271, 2018-2022[Abstract/Free Full Text]
  39. Liu, J., and Kane, P. M. (1996) Biochemistry 35, 10938-10948[CrossRef][Medline] [Order article via Infotrieve]
  40. Liu, Q., Leng, X. H., Newman, P. R., Vasilyeva, E., Kane, P. M., Forgac, M. (1997) J. Biol. Chem. 272, 11750-11756[Abstract/Free Full Text]
  41. Gietz, D., St. Jean, A., Woods, R. A., Schiestl, R. H. (1992) Nucleic Acids Res. 20, 1425[Medline] [Order article via Infotrieve]
  42. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1992) Short Protocols in Molecular Biology, Wiley, New York
  43. Yamashiro, C. T., Kane, P. M., Wolczyk, D. F., Preston, R. A., Stevens, T. H. (1990) Mol. Cell. Biol. 10, 3737-3749[Medline] [Order article via Infotrieve]
  44. Roberts, C. J., Raymond, C. K., Yamashiro, C. T., Stevens, T. H. (1991) Methods Enzymol. 194, 644-661[Medline] [Order article via Infotrieve]
  45. Kane, P. M., Yamashiro, C. T., and Stevens, T. H. (1989) J. Biol. Chem. 264, 19236-19244[Abstract/Free Full Text]
  46. Kane, P. M., Kuehn, M. C., Howald-Stevenson, I., and Stevens, T. H. (1992) J. Biol. Chem. 267, 447-454[Abstract/Free Full Text]
  47. Wishart, D. S., Boyko, R. F., Willard, L., Richards, F. M., Sykes, B. D. (1994) Comp. Biol. Sci. 10, 121-132
  48. Brünger, A. T. (1987) X-PLOR: A System for X-ray Crystallography and NMR, Yale University Press, New Haven, CT
  49. Drose, S., Bindseil, K. U., Bowman, E. J., Siebers, A., Zeeck, A., Altendorf, K. (1993) Biochemistry 32, 3902-3906[Medline] [Order article via Infotrieve]
  50. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  51. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J. (1951) J. Biol. Chem. 193, 265-275[Free Full Text]
  52. Nelson, H., and Nelson, N. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3503-3507[Abstract]
  53. Taiz, L., Nelson, H., Maggert, K., Morgan, L., Yatabe, B., Taiz, S. L., Rubinstein, B., Nelson, N. (1994) Biochim. Biophys. Acta 1194, 329-334[Medline] [Order article via Infotrieve]
  54. Cross, R. L, Cunningham, D., Miller, C. G., Xue, Z., Zhou, J. M., Boyer, P. D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5715-5719[Abstract]
  55. Weber, J., Wilke-Mounts, S., Lee, R. S., Grell, E., Senior, A. E. (1993) J. Biol. Chem. 268, 20126-20133[Abstract/Free Full Text]
  56. Weber, J., Lee, R. S., Grell, E., Wise, J. G., Senior, A. E. (1992) J. Biol. Chem. 267, 1712-1718[Abstract/Free Full Text]
  57. Ho, M. N., Hirata, R., Umemoto, N., Ohya, Y., Takatsuki, A., Stevens, T. H., Anraku, Y. (1993) J. Biol. Chem. 268, 18286-18292[Abstract/Free Full Text]
  58. Kibak, H., van Eckhout, D., Cutler, T., Taiz, S. L., Taiz, L. (1993) J. Biol. Chem. 268, 23325-23333[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.